OKYO Pharma Finalizes $18.5M Public Offering, Issuing 10.8M Shares at $1.85

summarizeSummary

OKYO Pharma Ltd. finalized an underwritten public offering of 10.8 million shares at $1.85 each, raising approximately $18.5 million in net proceeds to fund clinical development and operations, despite anticipating further capital needs.

check_boxKey Events

• Public Offering Finalized

  OKYO Pharma Ltd. finalized an underwritten public offering of 10,815,000 ordinary shares at a public offering price of $1.85 per share, generating approximately $18.5 million in net proceeds after expenses.

• Substantial Dilution

  The offering will increase the number of outstanding ordinary shares by over 26%, from 40,555,197 to 51,370,197, resulting in significant dilution for existing shareholders.

• Capital for Clinical Development

  Proceeds are intended for clinical development of product candidates, general corporate purposes, and working capital, which is crucial for the company's ongoing operations and advancement of its lead candidate, urcosimod.

• Addresses Going Concern, but Future Capital Needs Remain

  This capital raise helps address the company's liquidity position, which previously included a 'going concern' warning. However, the filing notes that these proceeds are for a 'short period of time' and the company expects to need additional funds in the future.

auto_awesomeAnalysis

OKYO Pharma Ltd. has finalized the terms of its underwritten public offering, raising approximately $18.5 million in net proceeds by selling 10,815,000 ordinary shares at $1.85 per share. This offering, which was priced at a slight discount to the last reported share price of $1.95 on February 11, 2026, represents a substantial capital infusion for the clinical-stage biopharmaceutical company. The proceeds are earmarked for clinical development of its product candidates, general corporate purposes, and working capital. While this capital raise is critical for extending the company's operational runway, especially in light of a prior "going concern" warning, the filing explicitly states that these funds are expected to be sufficient for only a short period, indicating a continued need for future capital raises and potential further dilution.